The tablet is a sulfate-based preparation that’s an alternative to liquid solutions. Sebela developed the pill for patients who have had difficulty completing preparation solutions in the past.
In a clinical trial with 515 patients, 92 percent of patients achieved a successful level of bowel cleansing after taking Sutab, and 78 percent of patients said they’d take it again for a future colonoscopy.
In a second trial, 92 percent to 95 percent achieved successful cleansing in all segments of the colon.
Sutab will be available to patients on Jan. 1, 2021.
More articles on surgery centers:
10 recent ASC leadership moves
Virginia ASC takes infection prevention to new level — 3 insights
Surgery Partners goes all-in on cardiology — 5 quotes on its quarterly performance
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.